Schedule 13G ownership disclosure
Agios Pharmaceuticals Inc
Common Stock · CUSIP: 00847X104
Event date: 2025-06-01
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Bellevue Group AG
Shares: 3,515,150.00 · Class: 6.1%
- Bellevue Asset Management AG
Shares: 3,515,150.00 · Class: 6.1%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-25-066212
- Form type
- SCHEDULE 13G
- Filer
- AGIOS PHARMACEUTICALS, INC.
- CIK
- CIK 1439222
- Filed
- Jul 07, 2025
- Reporting period
- Jun 01, 2025
- Description
- Schedule 13G beneficial ownership